Recent Updates
Recently added Catalysts
IMVT Positive Sentiment Score: 80/100

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Wednesday, January 3, 2024 1 min read
Key Takeaway: Immunovant, Inc. announced that its CEO, Pete Salzmann, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation aims to outline the company's initiatives and developments in targeting autoimmune diseases through anti-FcRn technology. Stakeholders can access the live webcast and an archived version on Immunovant's website post-presentation. This showcases the company's ongoing commitment to innovation in immunology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is actively engaging with stakeholders by presenting at a significant healthcare conference.
  • The company is focused on addressing the needs of people with autoimmune diseases through innovative therapies.
  • Immunovant has a strong leadership presence with CEO Pete Salzmann presenting at the conference.

Full Press Release Details

NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am ET.
The presentation will be webcast live and can be accessed at https://www.immunovant.com/investors/news-events. An archived webcast will be available for a limited time on Immunovant’s website.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.
Chau Cheng, PhD, MBA
Vice President, Investor Relations

Frequently Asked Questions

When will Immunovant present at the J.P. Morgan Conference?

Immunovant will present on January 9, 2024, at 10:30 am ET.

How can I access the Immunovant conference presentation?

The presentation will be webcast live on Immunovant's website.

What is the focus of Immunovant, Inc.?

Immunovant focuses on developing therapies for autoimmune diseases.

Who is presenting at the J.P. Morgan Healthcare Conference?

Pete Salzmann, M.D., the CEO, will provide the corporate overview.

What technology does Immunovant specialize in?

Immunovant specializes in anti-FcRn technology for autoimmune treatments.

Tags: IMVT Viatris Investor Conferences Healthcare Immunovant autoimmune diseases J.P. Morgan Healthcare Conference Pete Salzmann anti-FcRn technology
Last updated: Jan 3, 2024